Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Interest & Investment Income: 2017-2024

Historic Interest & Investment Income for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to $17.2 million.

  • BridgeBio Pharma's Interest & Investment Income rose 89.29% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.2 million, marking a year-over-year increase of 11.36%. This contributed to the annual value of $17.2 million for FY2024, which is 4.37% down from last year.
  • According to the latest figures from FY2024, BridgeBio Pharma's Interest & Investment Income is $17.2 million, which was down 4.37% from $18.0 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Interest & Investment Income registered a high of $18.0 million during FY2023, and its lowest value of $1.1 million during FY2021.
  • Moreover, its 3-year median value for Interest & Investment Income was $17.2 million (2024), whereas its average is $14.3 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first crashed by 71.78% in 2021, then spiked by 565.67% in 2022.
  • BridgeBio Pharma's Interest & Investment Income (Yearly) stood at $4.0 million in 2020, then slumped by 71.78% to $1.1 million in 2021, then spiked by 565.67% to $7.5 million in 2022, then spiked by 139.17% to $18.0 million in 2023, then dropped by 4.37% to $17.2 million in 2024.